Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 17;6(4):709–728. doi: 10.20517/cdr.2023.62

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023.

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

SC263 xenograft models in CB17 Scid mice are unsuitable for investigating cetuximab resistance. (A) Tumor kinetics after s.c. injection with 2.5 × 10⁶ + 25% Matrigel SC263-S cells in CB17 Scid mice (n = 27); (B) Tumor kinetics after s.c. injection with 10 × 10⁶ + 12 mg/mL Geltrex SC263-S cells in CB17 Scid mice (n = 10). Each line represents the data of one individual mouse; (C) Tumor kinetics of SC263-R tumor-bearing CB17 Scid mice following treatment with vehicle (PBS, n = 6), cetuximab low (2.5 mg/kg, n = 7), cetuximab medium (10 mg/kg, n = 7), and cetuximab high (50 mg/kg, n = 7). The green area in the graph represents the treatment period (starting from day 7). Data represent mean ± SD. HNSCC: Head and neck squamous cell carcinoma; -S: cetuximab-sensitive HNSCC cell line; -R: cetuximab-resistant HNSCC cell line; s.c.: subcutaneous.